Recruiting Clinical Trials

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

By April 24, 2017 No Comments

Condition

Mesothelioma

Estimated Enrollment: 20

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label

Study ID Numbers: H-36952

Study First Received: October 19, 2015

Last Updated: December 6, 2016

Estimated Primary Completion Date: May 2018

 

Primary Outcome Measures:

Intratumoral ratio of CD8 T cells to regulatory T cells (CD8/Treg). [Ratio]|The percentage of inducible T-cell co-stimulator (ICOS) + CD4 T cells.|The tumor expression programmed death-ligand 1 (PD-L1). [Semi-quantitative assessment: 0, 1+, 2+, 3+, 4+]

Sponsors and Collaborators:

Baylor College of Medicine

Website Link: https://ClinicalTrials.gov/show/NCT02592551

Leave a Reply

Call Now